Usefulness of immunocytochemistry for the detection of the BRAF V600E mutation in circulating tumor cells from metastatic melanoma patients

Journal of Investigative Dermatology

Volumn 133, Issue 5, 2013, Pages 1378-1381

  Hofman, Véronique ^a,b   Ilie, Marius ^a,b   Long Mira, Elodie ^a,b   Giacchero, Damien ^c   Butori, Catherine ^b   Dadone, Bérengère ^a   Selva, Eric ^a   Tanga, Virginie ^a   Passeron, Thierry ^c   Poissonnet, Gilles ^d   Emile, Jean François ^e   Lacour, Jean Philippe ^c   Bahadoran, Philippe ^c   Hofman, Paul ^a,b  

^a PASTEUR HOSPITAL   (France)

^b UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d CENTRE ANTOINE LACASSAGNE   (France)

^e HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE;

ADVANCED CANCER; AMINO ACID SUBSTITUTION; BLOOD SAMPLING; CELL STRUCTURE; CIRCULATING TUMOR CELL; CLINICAL PRACTICE; CYTOPATHOLOGY; ENZYME ACTIVATION; GENE IDENTIFICATION; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LETTER; METASTATIC MELANOMA; PATIENT CARE; PRIORITY JOURNAL; PYROSEQUENCING; SENSITIVITY AND SPECIFICITY; TARGETED GENE REPAIR;

EID: 84876688489     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.485     Document Type: Letter

References (14)

1. Alix-Panabières C, Schwarzenbach H, Pantel K (2012) Circulating tumor cells and circulating tumor DNA. Annu Rev Med 63:199-215
2. Board RE, Ellison G, Orr MC et al. (2009) Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br J Cancer 101:1724-30
3. Capper D, Berghoff AS, Magerle M et al. (2012) Immunohistochemical testing of BRAF V600E status in 1, 120 tumor tissue samples of patients with brain metastases. Acta Neuro-pathol 123:223-33
4. Davies H, Bignell GR, Cox C et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-54
5. De Giorgi V, Pinzani P, Salvianti F et al. (2010) Application of a filtration-and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J Invest Dermatol 130:2440-7
6. Flaherty KT (2012) Targeting metastatic melanoma. Annu Rev Med 63:171-83
7. Gonzalez de Castro D, Angulo B, Gomez B et al. (2012) A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens. Br J Cancer 107:345-51
8. Ilie M, Long E, Butori C et al. (2012) ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. Ann Oncol 23:2907-13
9. Longo DL (2012) Tumor heterogeneity and personalized medicine. N Engl J Med 366: 956-7
10. Paterlini-Brechot P (2011) Organ-specific markers in circulating tumor cell screening: an early indicator of metastasis-capable malignancy. Future Oncol 7:849-71
11. Paterlini-Brechot P, Benali NL (2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 253: 180-204
12. Rubinstein JC, Sznol M, Pavlick AC et al. (2010) Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 8:67
13. Sakaizawa K, Goto Y, Kiniwa Y et al. (2012) Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer 106:939-46
14. Wan PT, Garnett MJ, Roe SM et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-67